Evidence map›Paper›PMID 39524682›Full record

ArticleACS omega2024

Boronic Acid-Based Glucose Detection for Liver Three-Dimensional Cellular Models.

Wessal Hussein, Doron Goldberg, Guy Tenzer, Isaac Bentwich, Yossi Haran, Tamar Getter

Abstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wessal HusseinBioAI Drug Safety Prediction Platform, Quris, HaNatsiv St 6, Tel Aviv-Yafo 6701033, Israel.
Doron GoldbergBioAI Drug Safety Prediction Platform, Quris, HaNatsiv St 6, Tel Aviv-Yafo 6701033, Israel.
Guy TenzerBioAI Drug Safety Prediction Platform, Quris, HaNatsiv St 6, Tel Aviv-Yafo 6701033, Israel.
Isaac BentwichBioAI Drug Safety Prediction Platform, Quris, HaNatsiv St 6, Tel Aviv-Yafo 6701033, Israel.
Yossi HaranBioAI Drug Safety Prediction Platform, Quris, HaNatsiv St 6, Tel Aviv-Yafo 6701033, Israel.
Tamar GetterBioAI Drug Safety Prediction Platform, Quris, HaNatsiv St 6, Tel Aviv-Yafo 6701033, Israel.ORCID https://orcid.org/0000-0001-8703-2459

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver 3D cell models are regularly employed as a screening platform for predicting the metabolic safety of drugs, by monitoring the physiological responses of the spheroids, through the measurement of relevant markers of normal liver physiology, notably glucose. Measuring glucose levels within the spheroids and their surroundings provides insight into the metabolic homeostasis of liver cells and may be employed as an indication of potential drug-induced toxicity. Several ortho-aminomethyl phenylboronic acid (PDBA) glucose sensors have been developed. Most recently, Mc-CDBA ((((((2-(methoxycarbonyl)anthracene-9,10-diyl)bis(methylene)) bis(methylazanediyl))bis(methylene))bis(4-cyano-2,1-phenylene))diboronic acid) was reported. Although Mc-CDBA exhibits good water solubility and sensitivity toward glucose, its ability for intra- and extracellular glucose monitoring in spheroids has not been determined. Here, we present a set of Mc-CDBA derivatives: carboxylic (BA) and amide (BA 5)-based Mc-CDBA sensors for extra- and intracellular glucose monitoring, respectively. Both sensors exhibit superior spectroscopic features. BA 5 showed selective intracellular accumulation in liver spheroids and exhibited more than 3-fold higher basal fluorescence sensitivity compared to Mc-CDBA. These observations led to the development of an extracellular hydrogel-embedded sensor (HG-BA 21) to monitor extracellular glucose levels under persistent solution flow mimicking physiological conditions. We have therefore demonstrated that the sensors developed by our team are suitable for a variety of assays, notably with liver spheroids, and provide powerful new tools for organ-on-a-chip applications predicting drug-induced liver injury in the early stages of drug development.

Identifiers

PMID39524682
PMCPMC11541505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.